PATENT CLAIM ANALYSIS

Application Number: 16146965
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["435", "455000"]

Abstract:
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Claim (Index 13):
The method of  claim 8 , wherein the transgenic regulatory region is an exogenous constitutive, or inducible promoter.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.33333
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15813917', '15019449', '11667410', '15840930', '15590587']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5717197189376629
- 35 USC 102 Novelty (BERT): 0.5122573180025894
- Combined Prediction Score: 0.5657734788441555
- Mean Citation Score: 201.67368
- Max Citation Score: 209.61426
- Similarity Product: 111.0787723830378

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test